SecBot SecBot
8-K ·Filed Aug 6, 2026

FHTX

Foghorn Therapeutics Inc.
MIXED
Impact 5/10
Horizonmonths Processed3mo ago SEC0001628280-26-053817
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The narrower net loss is a positive headline, but the one-time nature of the revenue catch-up and the CBPd-171 delay create uncertainty. Monitor for updated CBPd-171 guidance and any data readouts from the FHD-909 Phase 1 trial, which are the primary catalysts.

DirectionMixed
Confidencemedium
Horizonmonths

FHD-909

● Neutral Named in this 8-K
Impact
Phase
Phase 1
Time to market
Unknown — the drug is in early Phase 1 dose-escalation. Assuming successful development, a potential approval would be several years away (likely 2029+).
Next catalyst
None dated

What to watchMonitor for any announced Phase 1 data readout date or interim results from the FHD-909 dose-escalation trial, which would be the next major catalyst. Also watch the December 2026 Lilly collaboration term expiration for potential restructuring or milestone news. The stock's ~144% implied upside to analyst targets reflects optimism about the platform, but early-stage clinical risk remains substantial.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$5.57
T+0 close · Aug 6, 2026 · via day close
Latest settled
−62.66%
T+60 · $2.08
Vs SPY
−60.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $5.57entry
  2. T+1 · 3mo ago +8.98%α +8.37% · $6.07
  3. T+5 · 3mo ago +16.52%α +15.30% · $6.49
  4. T+20 · 3mo ago −12.57%α −13.17% · $4.87
  5. T+60 · 18d ago −62.66%α −60.99% · $2.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Foghorn Therapeutics reported Q2 2026 financial results with a net loss of $7.2M, significantly narrower than the $17.9M loss in Q2 2025, driven by a $14.2M cumulative catch-up adjustment in collaboration revenue from the Lilly agreement. The company highlighted its FHD-909 Phase 1 trial advancing as planned and a new immunology/inflammation program, but disclosed a delay in the CBPd-171 timeline due to a CRO operational issue. The narrower net loss is a positive, but the one-time revenue adjustment and the CBPd-171 delay temper the outlook for a pre-revenue biotech.

Key Financial Metrics

EPS
−$0.10
est −$0.23 · +56.5%
Revenue
$16.1M
est $7.9M · +103.4% · +112.7% YoY
Rating
in line

Key Facts

  • Net loss narrowed to $7.2M in Q2 2026 from $17.9M in Q2 2025, largely due to a $14.2M cumulative catch-up adjustment in collaboration revenue.
  • Collaboration revenue surged to $16.1M from $7.6M YoY, driven by the catch-up adjustment tied to the scheduled expiration of the Lilly research term in December 2026.
  • Cash, cash equivalents, and marketable securities stood at $167.6M, providing runway into the first half of 2028.
  • The CBPd-171 (FHT-171) timeline has been delayed due to an unexpected operational issue at a third-party CRO; updated guidance is pending.
  • FHD-909 Phase 1 dose-escalation trial is on track with NSCLC as the primary target population.
  • The company is accelerating a novel oral small molecule in immunology and inflammation toward an IND in 2027.

Financial Impact

Net loss improved by $10.7M YoY, but this was driven by a $14.2M non-recurring catch-up adjustment. Cash burn remains significant at ~$7.2M per quarter from operations.

net losscollaboration revenuecash

Risk Factors

  • CBPd-171 timeline delay could signal broader CRO/operational risks.
  • Lilly collaboration research term expires in December 2026, creating a potential revenue cliff.
  • Pre-revenue biotech with no approved products; stock is highly sensitive to pipeline updates and cash runway.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-053817
Document: a2026augustfoghorninvest.htm0001628280-26-053817
Document: fhtx-20260806.htm0001628280-26-053817
Document: 0001628280-26-053817-index-headers.html0001628280-26-053817
Document: 0001628280-26-053817-index.html0001628280-26-053817
Document: 0001628280-26-053817.txt0001628280-26-053817
8-K Data (Synthetic)0001628280-26-053817

Track record

9 reports on FHTX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +31.85% at T+5 after the Oct 1, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $1.81 Now $1.79 −0.83% settles Dec 15
  2. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $2.04 Now $1.79 −12.25% settles Dec 8
  3. Oct 5, 20266w ago 3 Neutral 2/10 Entry $1.97 to $2.12 Now $1.79 −9.14% ▲ +7.36% +10.26% vs SPY
  4. Oct 5, 20266w ago SC 13G/A Neutral 4/10 Entry $1.97 to $2.13 Now $1.79 −9.14% ▲ +8.12% +11.30% vs SPY
  5. Oct 1, 20266w ago 8-K Bearish 7/10 Entry $2.92 to $2.09 Now $1.79 +38.70% ▲ +28.42% +29.13% vs SPY
  6. Aug 6, 202614w ago 8-K Mixed 5/10 Viewing Entry $5.57 to $4.87 Now $1.79 −67.86% ▼ −12.57% −13.17% vs SPY
  7. May 7, 202627w ago 8-K Neutral 3/10 Entry $4.20 to $3.64 Now $1.79 −57.38% ▼ −13.33% −16.47% vs SPY
  8. Apr 21, 202629w ago Press Release Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
  9. Apr 21, 202629w ago 8-K Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026